Digest Network Come funziona
Network
/
Società
Be
Non verificato

BeiGene, Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

38 comunicati stampa

Guarda tutti i comunicati
27/05/2025
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
Industria
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0
22/05/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0
14/05/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0
13/05/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0
07/05/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0
29/04/2025
Legge/Diritto
Industria
Oncologia
Associazioni/Professionisti
Salute
Biotecnologia
Farmaceutica
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0
17/04/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
BeiGene to Announce First Quarter 2025 Financial Results on May 7
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0
03/04/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0
31/03/2025
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0
04/03/2025
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
Fonte
BeiGene, Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0